AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lacidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 1532 | 103890-78-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 4 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 18 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lower urinary tract symptoms | 54.36 | 35.20 | 7 | 865 | 107 | 90627468 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Procalcitonin abnormal | 70.33 | 30.82 | 12 | 1353 | 383 | 42619587 |
| Encephalomalacia | 58.49 | 30.82 | 12 | 1353 | 1049 | 42618921 |
| Lymphocyte count increased | 56.42 | 30.82 | 15 | 1350 | 4049 | 42615921 |
| PO2 decreased | 53.28 | 30.82 | 12 | 1353 | 1629 | 42618341 |
| PCO2 decreased | 52.21 | 30.82 | 12 | 1353 | 1782 | 42618188 |
| Acquired macroglossia | 46.26 | 30.82 | 6 | 1359 | 25 | 42619945 |
| Device related sepsis | 43.00 | 30.82 | 12 | 1353 | 3875 | 42616095 |
| Monocyte count increased | 38.47 | 30.82 | 12 | 1353 | 5682 | 42614288 |
| Drug interaction | 35.44 | 30.82 | 43 | 1322 | 266956 | 42353014 |
| Procedural haemorrhage | 32.47 | 30.82 | 9 | 1356 | 2832 | 42617138 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Procalcitonin abnormal | 75.42 | 26.16 | 12 | 2220 | 397 | 110586670 |
| Encephalomalacia | 59.84 | 26.16 | 12 | 2220 | 1490 | 110585577 |
| Lymphocyte count increased | 59.42 | 26.16 | 16 | 2216 | 7187 | 110579880 |
| PO2 decreased | 50.99 | 26.16 | 12 | 2220 | 3136 | 110583931 |
| PCO2 decreased | 50.94 | 26.16 | 12 | 2220 | 3149 | 110583918 |
| Drug interaction | 48.79 | 26.16 | 55 | 2177 | 500128 | 110086939 |
| International normalised ratio increased | 48.75 | 26.16 | 27 | 2205 | 86745 | 110500322 |
| Device related sepsis | 40.43 | 26.16 | 12 | 2220 | 7635 | 110579432 |
| Lower urinary tract symptoms | 38.73 | 26.16 | 7 | 2225 | 499 | 110586568 |
| Acquired macroglossia | 36.08 | 26.16 | 6 | 2226 | 262 | 110586805 |
| Scrotal oedema | 35.75 | 26.16 | 8 | 2224 | 1673 | 110585394 |
| Monocyte count increased | 33.91 | 26.16 | 12 | 2220 | 13281 | 110573786 |
| Procedural haemorrhage | 30.81 | 26.16 | 9 | 2223 | 5418 | 110581649 |
| Attention deficit hyperactivity disorder | 27.95 | 26.16 | 8 | 2224 | 4483 | 110582584 |
| Melaena | 27.04 | 26.16 | 17 | 2215 | 68740 | 110518327 |
| Splenomegaly | 26.80 | 26.16 | 12 | 2220 | 24486 | 110562581 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08CA09 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
Related Drugs by ATC class:
C08CA Dihydropyridine derivatives 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-gated L-type calcium channel | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.25 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.64 | DRUG MATRIX | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 6.05 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.77 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
| Androgen receptor | Transcription factor | Ki | 5.58 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4025250 | VUID |
| N0000179165 | NUI |
| D04657 | KEGG_DRUG |
| 4025250 | VANDF |
| C0064568 | UMLSCUI |
| CHEBI:135737 | CHEBI |
| CHEMBL460291 | ChEMBL_ID |
| DB09236 | DRUGBANK_ID |
| C060285 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11740 | IUPHAR_LIGAND_ID |
| 6093 | INN_ID |
| 260080034N | UNII |
| 5311217 | PUBCHEM_CID |
| 28382 | RXNORM |
| 004453 | NDDF |
| 319299000 | SNOMEDCT_US |
| 395764001 | SNOMEDCT_US |
Pharmaceutical products:
None